Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 and Sorafenib in Advanced Hepatocellular Carcinoma
NCT00872014Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2009
- Primary completion
- Oct 2011
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of trebananib in hepatocellular carcinoma (HCC), sponsored by Amgen. Started Aug 2009; status: completed.
02
Drugs
trebananib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00872014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00872014.